德伦环烷 | 120444-72-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 德伦环烷
• 英文名称: (1R,2S,4R)-(-)-2-[(2'-{N,N-dimethylamino}-ethoxy-)]-2-[phenyl]-1,7,7,-tri-[methyl]-bicyclo[2.2.1]heptane fumarate (1:1)
• 英文别名: (1R,2S,4R)-(-)-N,N-dimethyl-2-{(1,7,7-trimethyl-2-phenylbicyclo-[2,2,1]-hept-2-yl)oxy}-ethaneamine-2-(E)-butendioate；(1R,2S,4R)-(-)-N,N-dimethyl-2-{(1,7,7-trimethyl-2-phenylbicyclo-[2,2,1]-hept-2-yl)oxy}-ethamine-2-(E)-butendioate；deramciclane fumarate；deramciclane；EGIS-3886；(1R,2S,4R)-(-)-2-phenyl-2-(2'-dimethylaminoethoxy)-1,7,7-trimethyl-bicyclo/2.2.1/heptane (E)-2-butenedioate；(E)-but-2-enedioic acid;N,N-dimethyl-2-[[(1R,2S,4R)-1,7,7-trimethyl-2-phenyl-2-bicyclo[2.2.1]heptanyl]oxy]ethanamine
• CAS: 120444-72-6
• 化学式: C₄H₄O₄*C₂₀H₃₁NO
• 分子量: 417.546
• InChiKey: RFQWRWCCNQNACG-HJYQBBATSA-N

物化性质

• 熔点：
  210-213°
• 比旋光度：
  43620 -88.0° ± 1 (c = 0.4 in DMSO)

计算性质

• 辛醇/水分配系数(LogP)：
  4.02
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  德伦环烷 、 甘露醇 、 、 、 、 Stearic acid magnesium salt 反应 0.33h， 以to produce lentiform tablets of 9 mm diameter的产率得到德伦环烷
  参考文献：
  名称：

  Process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose

  摘要：

  该发明涉及一种制备片剂的方法，该片剂可以被良好压缩且具有良好的机械强度，该片剂由具有不良压片性能的药物活性成分制成。在该发明的过程中，使用一种制粒液体，该制粒液体是5-30％微晶纤维素的悬浮液，其中90％的微晶纤维素粒径小于50 Sg（m）m，微晶纤维素的数量是指最终片剂质量中的微晶纤维素在水和/或乙醇和/或异丙醇中的含量，该悬浮液中还可以含有部分颗粒的成分以溶解形式存在。

  公开号：

  US20050163836A1
• 作为产物：
  描述：

  德伦环烷 在 富马酸 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以97.5%的产率得到德伦环烷
  参考文献：
  名称：

  High purity (1R,2S,4R)-(-)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof

  摘要：

  该发明涉及高纯度的(1R,2S,4R)-(−)-2-[(2′-N,N-二甲基氨基乙氧基)]-2-[苯基]-1,7,7-三[甲基]-双环[2.2.1]庚烷及其药用可接受的酸盐，其含有不超过0.2%的(1R,3S,4R)-3-[(2′-N,N-二甲基氨基乙基)]-1,7,7-三[甲基]-双环[2.2.1]庚烷-2-酮和/或其药用可接受的酸盐。此外，该发明涉及制备这些化合物的方法。此外，该发明涉及含有1种或多种这些化合物的药物及其用途。

  公开号：

  US06335469B1

文献信息

• Process for preparing (1R,2S,4R)-(-)-2-[(2'-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof
  申请人：Egis Gyógyszergyár Rt.

  公开号：US06242386B1

  公开（公告）日：2001-06-05

  A process for preparing (1R,2S,4R)-(−)-2-[(2′-[N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo [2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof with higher yields and higher grades of purity.

  一种制备（1R,2S,4R）-（-）-2-［（2'-［N，N-二甲基氨基］-乙氧基］-2-［苯基］-1,7,7-三-［甲基］-双环［2.2.1］庚烷及其药用可接受的酸加盐的方法，其产率更高，纯度更高。
• Basic ethers and pharmaceutical compositions containing the same
  申请人：Egyt Gyogyszervegyeszeti Gyar

  公开号：US04342762A1

  公开（公告）日：1982-08-03

  The invention relates to novel basic ethers of the general formula /I/ and pharmaceutically acceptable acid addition salts and quaternary salts thereof, ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different and represent a C.sub.1-5 alkyl group or a C.sub.3-6 cycloalkyl group or they form, together with the adjacent nitrogen atom, a heterocyclic ring containing 4-7 carbon atoms and optionally a further hetero atom, e.g. an oxygen, sulfur or nitrogen atom, and this latter may be optionally substituted by a C.sub.1-3 alkyl, benzyl or phenyl group, R represents a phenyl, phenyl-/C.sub.1-3 alkyl/ or thienyl group optionally substituted by one or more halogen or C.sub.1-3 alkoxy substituent/s/, A represents a C.sub.2-5 straight or branched alkylene chain, and represents a valence bond of .alpha. or .beta. configuration. The new compounds of the general formula /I/ possess valuable anticonvulsive, motility inhibiting, hexobarbital narcose potentiating and analgesic effects, which are, in case of certain compounds, complemented by week antiserotonine, gastro-intestinal-tract inhibiting and antiinflammatory effects, and can be applied to advantage in the therapy.

  本发明涉及一种新型的基本醚，其通式为 /I/，以及其药学上可接受的酸加成盐和季铵盐，其中，R1和R2可以相同也可以不同，表示C1-5烷基或C3-6环烷基，或者它们与相邻的氮原子一起形成含有4-7个碳原子和可选的其他杂原子（例如氧、硫或氮原子）的杂环环，后者可以选择由C1-3烷基、苄基或苯基取代，R表示苯基、苯基/C1-3烷基/或噻吩基，可选地取代一个或多个卤素或C1-3烷氧基，A表示C2-5直链或支链烷基链，表示α或β构型的价键。通式/I/的新化合物具有有价值的抗惊厥、运动抑制、己巴比妥麻醉增强和镇痛作用，某些化合物的这些作用还可以辅以微弱的抗血清素、胃肠道抑制和抗炎作用，并可优势地用于治疗。
• High purity (1R, 2S, 4R) -(-) -2- [ (2' -{N,N-dimethylamino} -ethoxy) ] -2- [phenyl] -1, 7,7 -tri - [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof and a process for the preparation of these compounds as well as medicaments containing 1 or more of these compounds and their use
  申请人：——

  公开号：US20020040164A1

  公开（公告）日：2002-04-04

  The invention relates to high purity (1R,2S,4R)-(−)-2-[ (2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-methyl -bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2′-{N,N-dimethylamino}-ethyl)]-1 ,7,7-tri-[methyl]-bicyclo[2.2.1]heptane-2-one and/or of a pharmaceutically acceptable acid addition salt thereof. Furthermore the invention is concerned with a process for the preparation of these compounds. Moreover the invention relates to medicaments containing 1 or more of these compounds and their use.

  本发明涉及高纯度（1R，2S，4R）-（-）-2-［（2'-N，N-二甲基氨基）-乙氧基］-2-［苯基］-1,7,7-三甲基-双环［2.2.1］庚烷及其药学上可接受的酸盐，其中不含有超过0.2％的（1R，3S，4R）-3-［（2'-N，N-二甲基氨基）-乙基］-1,7,7-三［甲基］-双环［2.2.1］庚烷-2-酮和/或药学上可接受的酸盐。此外，本发明涉及制备这些化合物的方法。此外，本发明涉及含有1个或多个这些化合物的药物及其用途。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
  申请人：——

  公开号：US20040171696A1

  公开（公告）日：2004-09-02

  The compounds of the general Formula (I) (wherein R stands for hydrogen or methyl) can be used for the treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases. As compound of the general Formula I preferably -(1R,2S,4R)-(−)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane-fumarate can be used. 1

  通式（I）化合物（其中 R 代表氢或甲基）可用于治疗或预防以认知功能下降和/或受损为特征的疾病，或伴随其他疾病的精神残疾。作为通式 I 的化合物，优选使用-(1R,2S,4R)-(-)-2-(2-二甲基氨基乙氧基)-2-苯基-1,7,7-三甲基双环[2.2.1]庚烷富马酸盐。 1